Skip to main content

Advertisement

SpringerLink
Log in

99mTc(V)-DMSA seintigraphy in monitoring the response of bone disease to vitamin D3 therapy in renal osteodystrophy

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Renal osteodystrophy (ROD) is a common and serious complication for uremie patients and patients are treated with 1,25-dihydroxy vitamin D3. The bone scanning agent99mTc-phosphate has also been used to evaluate in ROD but it is not clear that bone scintigraphy has a role in the follow-up of treatment. In this study99mTc(V)-DMSA scintigraphy was performed in eleven patients [age 40.7 ± 17.3 (mean ± SD) yr] with ROD before and after vitamin D3 therapy. Images were obtained after hemodialysis performed following tracer injection to maintain normal blood levels of the radiopharmaceutical and to reduce soft tissue activity. Lumbar vertebra-to-soft tissue uptake ratios (LUR) were quantified with the planar99mTc(V)-DMSA images. Alkaline phosphatase and parathyroid hormone levels after treatment had significantly decreased compared with pre-therapy. In all patients there was visually decreased uptake in bone structures after treatment. After treatment the mean LUR ratio was significantly lower than those of before treatment (3.59 ± 2.63 vs. 1.65 ±0.62; p = 0.01). LUR values were correlated with pre-therapy alkaline phosphatase and parathyroid hormone. These findings indicated that99mTc(V)-DMSA scintigraphy is sensitive in evaluating the response of ROD to vitamin D3 therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lien JW, Wiegmann T, Rosenthall L, Kaye M. Abnormal99mTechnetium-tin-pyrophosphate bone scans in chronic renal failure.Clin Nephrol 1976; 6: 509–512.

    PubMed  CAS  Google Scholar 

  2. Alberts C, van der Schoot JB, Busemann-Sokole E. Bone scintigraphy and densitometry in symptomatic haemodialysis bone disease.Eur J Nucl Med 1981; 6: 505–509.

    PubMed  CAS  Google Scholar 

  3. Higuchi T, Hirano T, Inoue T, Aoki J, Ueki K, Wakamatsu R, et al. Pentavalent technetium-99m-dimercaptosuccinic acid scintigraphy in renal osteodystrophy.J Nucl Med 1998; 39: 541–543.

    PubMed  CAS  Google Scholar 

  4. Kida T, Narita S. A trial of semiquantitative analysis of whole body bone scintigraphy in renal osteodystrophy.Eur J Nucl Med 1987; 13: 36–40.

    Article  PubMed  CAS  Google Scholar 

  5. Dudczak R, Kletter K, Czembirek H, Derfler K, Marosi L, Salomonowitz E, et al. Radionuclide studies in chronically hemodialyzed patients. Bone scintigraphy for the evaluation and control of renal osteopathy.Wien Klin Wochenschr 1984; 96: 326–332.

    PubMed  CAS  Google Scholar 

  6. Vanherweghem JL, Dhaene M, Tielemans C, Dratwa M, Verbanck P, Bergmann P, et al. Predictive value of99mTc pyrophosphate bone scintigraphy for vitamin D trials in uraemia.Proc Eur Dial Transplant Assoc 1981; 18: 648–651.

    PubMed  CAS  Google Scholar 

  7. Hodson EM, Howman-Giles RB, Evans RA, Bautovich G, Hills EE, Sherbon K, et al. The diagnosis of renal osteodystrophy: a comparison of Technetium-99m-pyrophosphate bone scintigraphy with other techniques.Clin Nephrol 1981; 16: 24–28.

    PubMed  CAS  Google Scholar 

  8. Lam AS, Kettle AG, O’Doherty MS, Coakley AJ, Barrington SF, Blower PJ. Pentavalent99mTc-DMSA imaging in patients with bone metastases.Nucl Med Commun 1997; 18: 907–914.

    Article  PubMed  CAS  Google Scholar 

  9. Akbunar AT, Orhan B, Alper E. Bone-scan-like pattern with99mTc(V)-DMSA scintigraphy in patients with osteomalacia and primary hyperparathyroidism.Nucl Med Commun 2000; 21: 181–185.

    Article  PubMed  CAS  Google Scholar 

  10. Yuksel D, Ilgan S, Arslan N, Ugur O, Ozturk E, Bayhan H. The role of Tc-99m(V) DMSA scintigraphy in the evaluation of superscan on bone scintigraphy.Clin Nucl Med 2000; 2: 193–196.

    Article  Google Scholar 

  11. Wuifrank DA, Scheistraete KH, Small F, Fallais CJ. Analogy between tumor uptake of technetium(V)-99m dimercaptosuccinic acid (DMSA) and technetium-99m-MDP.Clin Nucl Med 1989; 14: 588–593.

    Article  Google Scholar 

  12. Kobayashi H, Shigeno C, Sakahara H, Yamamato T, Hosono M, Fujimoto R, et al. Three phase99mTc(V)DMSA scintigraphy in Paget’s disease: an indicator of pamidronate effect.Brit J Radiol 1997; 70: 1056–1059.

    PubMed  CAS  Google Scholar 

  13. de Graaf P, Pauwels EK, Vos PH, Schicht IM, te Velde J, de Graeff J. Observations on computerized quantitative bone scintigraphy in renal osteodystrophy.Eur J Nucl Med 1984; 9: 419–425.

    Article  PubMed  Google Scholar 

  14. Cannata-Andia JB. Adynamic bone and chronic renal failure: an overview.Am J Med Sci 2000; 320: 81–84.

    Article  PubMed  CAS  Google Scholar 

  15. Sanchez CP, Goodman WG, Salusky IB. Prevention of renal osteodystrophy in predialysis patients.Am J Med Sci 1999; 317: 398–404.

    Article  PubMed  CAS  Google Scholar 

  16. Goodman WG, Coburn JW. The use of 1,25-dihydroxy-vitamin D3 in early renal failure.Ann Rev Med 1992; 43: 227–237.

    PubMed  CAS  Google Scholar 

  17. Tigges S, Nance EP, Carpenter WA, Erb R. Renal osteodystrophy: imaging findings that mimic those of other diseases.AJR 1995; 165: 143–148.

    PubMed  CAS  Google Scholar 

  18. McAfee JG, Reba RC, Majd M. The musculoskeletal system. In: Wagner HN, Szabo Z, Buchanan JW (eds),Principles of Nucler Medicine. Pennsylvania: W.B. Saunders Company, 1995: 986–1020.

    Google Scholar 

  19. Malluche HH, Langub MC, Monier-Faugere MC. The role of bone biopsy in clinical practice and research.Kidney Int 1999; 56 (Suppl 73; renal bone disease): S20-S25.

    Article  Google Scholar 

  20. Ito M, Hayashi K, Noguchi M, Kitamori H. Evaluation of spinal bone changes in patients with chronic renal failure by CT and MR imaging with pathologic correlation.Acta Radiol 1994; 35: 291–295.

    PubMed  CAS  Google Scholar 

  21. Olmastroni M, Seracini D, Lavoratti G, Marin E, Masi A, Vichi G. Magnetic resonance imaging of renal osteodystrophy in children.Pediatr Radiol 1997; 27: 865–868.

    Article  PubMed  CAS  Google Scholar 

  22. Arici M, Erturk H, Altum B, Usalan C, Ulusoy S, Erdem Y, et al. Bone mineral density in haemodialysis patients: a comparative study of dual-energy X-ray absorptiometry and quantitative ultrasound.Nephrol Dial Transplant 2000; 15: 1847–1851.

    Article  PubMed  CAS  Google Scholar 

  23. Peacock M. Interpretation of bone mass determinations as they relate to fracture: implications for asymptomatic primary hyperparathyroidism.J Bone Miner Res 1991; 6 Suppl 2: S77–82; discussion S83–4.

    Article  PubMed  Google Scholar 

  24. Ryan PJ, Fogelman I. Bone scintigraphy in metabolic bone disease.Semin Nucl Med 1997; 27: 291–305.

    Article  PubMed  CAS  Google Scholar 

  25. Mari C, Catafau A, Carrio I. Bone scintigraphy and metabolic disorders.Q J Nucl Med 1999; 43: 259–267.

    PubMed  CAS  Google Scholar 

  26. Ryan PJ, Fogelman I. The bone scan: where are we now?Semin Nucl Med 1995; 25: 76–91.

    Article  PubMed  CAS  Google Scholar 

  27. Fogelman I, Bessent RG, Gordon D. A critical assessment of bone scan quantitation (bone to soft tissue ratios) in the diagnosis of metabolic bone disease.Eur J Nucl Med 1981; 6: 93–97.

    PubMed  CAS  Google Scholar 

  28. Fogelman I, Collier BD, Brown ML. Bone scintigraphy: part 3. bone scanning in metabolic bone disease.J Nucl Med 1993; 22: 47–52.

    Google Scholar 

  29. Fogelman I, Bessent R. Age-related alterations in skeletal metabolism-24-hr whole-body retention of diphosphonate in 250 normal subjects: concise communication.J Nucl Med 1982; 23: 296–300.

    PubMed  CAS  Google Scholar 

  30. Fogelman I, Pearson DW, Bessent RG, Tofe AJ, Francis MD. A comparison of skeletal uptakes of three diphosphonates by whole-body retention: concise communication.J Nucl Med 1981; 22: 880–883.

    PubMed  CAS  Google Scholar 

  31. Israel O, Gips S, Hardoff R, Rudoy J, Frajewicki V, Iosilevsky G, et al. Bone loss in patients with chronic renal disease: prediction with quantitative bone scintigraphy with SPECT.Radiology 1995; 196: 643–646.

    PubMed  CAS  Google Scholar 

  32. Israel O, Front D, Hardoff R, Ish-Shalom S, Jerushalmi J, Kolodny GM.In vivo SPECT quantitation of bone metabolism in hyperparathyroidism and thyrotoxicosis.J Nucl Med 1991; 32: 1157–1161.

    PubMed  CAS  Google Scholar 

  33. Messa C, Goodman WG, Hoh CK, Choi Y, Nissenson AR, Salusky IB, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry.J Clin Endocrinol Metab 1993; 77: 949–955.

    Article  PubMed  CAS  Google Scholar 

  34. Hirano T, Tomiyoshi K, Zhang YJ, Ishida T, Inoue T, Endo K. Preparation and clinical evaluation of technetium-99m dimercaptosuccinic acid for tumor scintigraphy.Eur J Nucl Med 1994; 21: 82–85.

    Article  PubMed  CAS  Google Scholar 

  35. Lam AS, Puncher MRB, Blower PJ.In vitro andin vivo studies with pentavalent technetium-99m-dimercaptosuccinic acid.Eur J Nucl Med 1996: 23: 1575–1582.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey

    Ali Sabikava & Sevim Hacimahmutoglu

  2. Department of Internal Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey

    Saniye Sen

  3. Department of Radiology, Faculty of Medicine, Trakya University, Edirne, Turkey

    Gökhan Pekindil

Authors
  1. Ali Sabikava
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saniye Sen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sevim Hacimahmutoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gökhan Pekindil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali Sabikava.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sabikava, A., Sen, S., Hacimahmutoglu, S. et al. 99mTc(V)-DMSA seintigraphy in monitoring the response of bone disease to vitamin D3 therapy in renal osteodystrophy. Ann Nucl Med 16, 19–23 (2002). https://doi.org/10.1007/BF02995287

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02995287

Key words

Search

Navigation